

**Venue:**

Auditorio Rafael del Pino  
Calle Rafael Calvo, 39A  
28010 Madrid

**Language:**

*The official language of the symposium is English.*

**Under the auspices of:**




**Organized by:**



**Symposium Secretariat:**



Monasterios de Suso y Yuso 34, 4-14-2, 28049 Madrid, Spain  
Tel.: +34 91 372 0203 · E-mail: [ibc@doctaforum.com](mailto:ibc@doctaforum.com)



# Innovation in Breast Cancer

Madrid, February 17<sup>th</sup>-18<sup>th</sup>, 2017

*IBC 2017*

[www.innovationinbreastcancer.com](http://www.innovationinbreastcancer.com)

FRIDAY, FEBRUARY 17th, 2017

- 15:00 - 15:15 Introduction**  
Miguel Martín  
Hospital General Universitario Gregorio Marañón, Madrid, Spain
- **SESSION I: CANCER DRUG DEVELOPMENT**  
Chair: Ramón Colomer  
Hospital Universitario de La Princesa, Madrid, Spain
- 15:15 - 15:45 PI3K as cancer TARGET**  
Jean J. Zhao  
Dana-Farber Cancer Institute, Boston, USA
- 15:45 - 16:15 Identification of actionable drug mutations for oncology drug development**  
Carlos Caldas  
Cancer Research UK Cambridge Institute, Cambridge, UK
- 16:15 - 16:45 Circulating tumor cells: A tool for cancer research?**  
Klaus Pantel  
Department of Tumor Biology, University Medical Center, Hamburg, Germany
- 16:45 - 17:15 Discussion**  
All
- 17:15 - 17:45 Coffee break**
- **SESSION II: CANCER BIOLOGY**  
Chair: Agustí Barnadas  
Hospital Santa Creu i Sant Pau, Barcelona, Spain
- 17:45 - 18:15 The microbioma and cancer**  
Robert F. Schwabe  
Columbia University, New York, USA
- 18:15 - 18:45 Breast cancer cell of origin: relevance for clinical practice**  
Alexandra Van Keymeulen  
IRIBHM, Brussels, Belgium
- 18:45 - 19:15 Cancer drug resistance: recent views**  
Daniel B. Longley  
Queen's University, Belfast, UK
- 19:15 - 19:45 Discussion**  
All

SATURDAY, FEBRUARY 18th, 2017

- **SESSION III: HER2-POSITIVE BREAST CANCER**  
Chair: Joan Albanell  
Hospital del Mar, Barcelona, Spain
- 08:30 - 09:00 Dual blockade in HER2-positive early breast cancer: standard therapy for all patients?**  
Luca Gianni  
Ospedale San Raffaele, Milan, Italy
- 09:00 - 09:30 Strengths and limitations of Trastuzumab emtansine in metastatic HER2-positive breast cancer (T-DM1)**  
Antonio González  
MD Anderson Cancer Center, Madrid, Spain
- 09:30 - 10:00 Treatment of HER2-positive breast cancer: what is new?**  
Miguel Martín  
Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 10:00 - 10:30 Discussion**  
All
- 10:30 - 11:00 Coffee break**
- **SESSION IV: HER2-NEGATIVE BREAST CANCER**  
Chair: Miguel Martín  
Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 11:00 - 11:30 Relevance of plasma ESR1 mutations for the treatment of metastatic estrogen receptor positive breast cancer**  
Nicholas C. Turner  
The Royal Marsden Hospital and Institute of Cancer Research, London, UK
- 11:30 - 12:00 Optimal duration of adjuvant hormonal therapy**  
José Enrique Alés  
Hospital Nuestra Señora de Sonsoles, Ávila, Spain
- 12:00 - 12:30 CDK 4/6 inhibition in metastatic breast cancer**  
Nadia Harbeck  
Leitung, Brustzentrum und Onkologische Tagesklinik, Frauenklinik der Universität München, Munich, Germany
- 12:30 - 13:00 Chemotherapy for triple negative breast cancer: are all drugs the same?**  
Javier Cortés  
Hospital Universitario Ramón y Cajal, Madrid, Spain / Vall d'Hebron Institute of Oncology, Barcelona, Spain
- 13:00 - 13:30 Discussion**  
All
- 13:30 Closing remarks**  
Miguel Martín  
Hospital General Universitario Gregorio Marañón, Madrid, Spain